OptimizeRx (NASDAQ:OPRX) Given New $12.50 Price Target at Stifel Nicolaus

OptimizeRx (NASDAQ:OPRX) had its target price upped by Stifel Nicolaus from $8.00 to $12.50 in a research note issued to investors on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other research firms have also recently commented on OPRX. B. Riley raised OptimizeRx to a “strong-buy” rating in a research report on Wednesday, March 12th. JMP Securities increased their price objective on OptimizeRx from $11.00 to $14.00 and gave the company a “market outperform” rating in a research report on Tuesday. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, OptimizeRx presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.38.

OptimizeRx Trading Up 19.7%

NASDAQ OPRX opened at $11.01 on Tuesday. OptimizeRx has a 12 month low of $3.78 and a 12 month high of $14.13. The stock has a market cap of $203.61 million, a P/E ratio of -8.28 and a beta of 1.28. The stock’s fifty day moving average price is $8.35 and its 200-day moving average price is $6.37. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29.

OptimizeRx (NASDAQ:OPRX) last released its earnings results on Monday, May 12th. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.19. OptimizeRx had a negative return on equity of 4.92% and a negative net margin of 27.41%. The firm had revenue of $21.93 million for the quarter, compared to analysts’ expectations of $18.69 million. As a group, equities analysts forecast that OptimizeRx will post -0.33 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director James Paul Lang acquired 321,408 shares of OptimizeRx stock in a transaction on Friday, March 14th. The shares were acquired at an average price of $7.60 per share, with a total value of $2,442,700.80. Following the purchase, the director now directly owns 389,452 shares in the company, valued at $2,959,835.20. The trade was a 472.35% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 6.10% of the stock is owned by insiders.

Institutional Trading of OptimizeRx

A number of large investors have recently added to or reduced their stakes in the company. Whetstone Capital Advisors LLC bought a new stake in OptimizeRx in the 4th quarter worth approximately $6,563,000. Royce & Associates LP bought a new stake in OptimizeRx in the 4th quarter worth approximately $5,198,000. Blair William & Co. IL increased its stake in OptimizeRx by 4.9% in the 1st quarter. Blair William & Co. IL now owns 631,031 shares of the company’s stock worth $5,465,000 after acquiring an additional 29,648 shares during the last quarter. Kennedy Capital Management LLC increased its stake in OptimizeRx by 57.8% in the 4th quarter. Kennedy Capital Management LLC now owns 594,000 shares of the company’s stock worth $2,887,000 after acquiring an additional 217,676 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in OptimizeRx by 9.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 444,167 shares of the company’s stock worth $2,159,000 after acquiring an additional 39,740 shares during the last quarter. Institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.